AEON Biopharma Receives Additional NYSE American Non-Compliance Notice Over Stockholders' Equity Deficit

On March 31, 2026, AEON Biopharma, Inc. received a notice of non-compliance from NYSE American LLC regarding continued listing standards. The notice cited a failure to meet Section 1003(a)(ii) of the Company Guide, which requires stockholders' equity of at least $4.0 million for companies with net losses in three of their four most recent fiscal years. As of December 31, 2025, AEON reported a stockholders' deficit of approximately $55 million. This follows a previous notice from February 2025 regarding a $2.0 million equity requirement. The company is currently operating under a compliance plan accepted by the exchange, which grants AEON until August 3, 2026, to regain compliance. The new notice does not immediately affect the listing of AEON's Class A Common Stock, which will continue to trade with a '.BC' indicator. AEON intends to execute its existing plan to address both equity shortfalls by the August 2026 deadline. The company is currently advancing ABP-450 as a biosimilar to BOTOX.